Heb y dull seiliedig ar dystiolaeth – set clir o feini prawf ac arbenigwyr clinigol annibynnol i werthuso effeithiolrwydd clinigol a chost-effeithiolrwydd meddyginiaethau newydd – ni fyddai modd i’r GIG nodi’r meddyginiaethau sy’n fwyaf cost-effeithiol a mwyaf effeithiol yn glinigol, neu hyd yn oed gwahaniaethu rhyngddynt.  Y dull seiliedig ar dystiolaeth sydd i’w gael yw’r dull mwyaf diogel i sicrhau’r triniaethau mwyaf effeithiol i gleifion a’r defnydd mwyaf effeithiol o adnoddau’r GIG.  Rwy’n annog cwmnïau fferyllol i gymryd rhan yn y broses werthuso a gofynnwn i Aelodau gefnogi’r dull hwn.
Without the evidence-based approach - a clear set of criteria and independent clinical experts to appraise the clinical and cost-effectiveness of new medicines - the NHS would have no way of identifying medicines which are the most cost-effective and most clinically effective, or even distinguishing between them. The evidence-based approach that is in place is the safest method for ensuring the most effective treatments for patients and the most effective use of NHS resources. I encourage pharmaceutical companies to engage in the appraisal process and I would ask Members to support this approach.